


---

## Figures and figure supplements

Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity

**Leen Farhat-Younis et al.**




**Figure 1.** IgM-induced signaling elicits cytotoxic response in macrophages and can be integrated to a CAR design. **(A)** Illustration of experimental setting. **(B)** B16F10 tumor size (mm<sup>2</sup>) in mice following prophylactic immunization with MoDC pulsed with tumor cells coated with allogeneic IgG or IgM (n=4). **(C)** Mean percentages of B16F10 melanoma cells stained for Annexin V/PI incubated with allogeneic IgG and IgM following incubation with MoDC (n=5). **(D–E)** Mean levels of Granzyme B and NO **(D)** and proinflammatory cytokines **(E)** in the supernatants of MoDC following overnight activation with Figure 1 continued on next page

*Figure 1 continued*

IgG and IgM immune complexes (n=5). **(F)** Mean fluorescent intensity (MFI) of MAPK enzymes in MoDC following activation for 20 min with IgG and IgM tumor immune complexes (n=5). **(G)** Illustration representing CAR-macrophage design. **(H)** Confocal microscopy images of HEK293FT cells 24 hr post-transfection with CAR plasmids and membranous wasabi. **(I)** Representative FACS analysis of HEK293FT cells 24 hr post-transfection with CAR plasmids. Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t-test (\* denote  $p < 0.05$ , \*\*\* denote  $p < 0.001$ , \*\*\*\* denote  $p < 0.0001$ ).

© 2024, BioRender Inc. Figure 1A, G was created using [BioRender](#), and is published under a [CC BY-NC-ND](#) license. Further reproductions must adhere to the terms of this license.




**Figure 2.** scFv is not expressed by myeloid cells. **(A)** Confocal microscopy images of DC 2.4 cells 24 hr post-transfection with CAR plasmids and membranous wasabi. **(B)** Representative FACS analysis of DC 2.4 cells 24 hr post-transfection with CAR plasmids. **(C)** Percentages of transfected cells 24 hr post-transfection (n=4). **(D)** Confocal microscopy images of THP-1 cells 72 hr post-lentiviral infection with CAR-C5aR-mCherry and tdTomato plasmids. **(E)** Percentages of transfected human cell lines 72 hr following transduction (n=4). **(F–G)** Representative confocal microscopy **(F)** and mean **Figure 2 continued on next page**



*Figure 2 continued*

percentages (**G**) of cells expressing chimeric molecules 24 hr after transfection. (**H–I**) Representative confocal microscopy (**H**) and mean percentages of cells (**I**) expressing chimeric molecules 24 hr following transfection (n=4). Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t-test (\*\* denote  $p < 0.01$ , \*\*\*\* denote  $p < 0.0001$ ).

© 2024, BioRender Inc. Figure 2F, H was created using [BioRender](#), and is published under a [CC BY-NC-ND](#) license. Further reproductions must adhere to the terms of this license.




**Figure 2—figure supplement 1.** scFv is not expressed by myeloid cells. **(A)** Confocal microscopy images of RAW264.7 cells transfected with scFv-based chimeric receptors. **(B–C)** Confocal microscopy images **(B)** and mean expression percentages **(C)** of HEK293FT and DC2.4 cells 24 hr post-transfection with TA99 scFv (n=4). **(D–E)** Confocal microscopy images of HEK293FT and DC 2.4 cells 24 hr post-transfection with αCD19 scFv **(D)** and with CD8-

Figure 2—figure supplement 1 continued on next page

*Figure 2—figure supplement 1 continued*


transmembrane portion only (**E**). Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t test.

© 2024, BioRender Inc. Figure 2—figure supplement 1B, D and E was created using [BioRender](#), and is published under a [CC BY-NC-ND](#) license. Further reproductions must adhere to the terms of this license.




**Figure 3.** Both VH and VL domains prevent expression of ScFv in myeloid cells. **(A)** Confocal microscopy images of DC 2.4 cells 24 hr post-transfection with αCD19-scFv GFP plasmid. **(B)** Geometric mean of GFP-positive cells 24 hr post-transfection with different αCD19- and TA99- ScFv GFP constructs in DC2.4 (n=3). **(C)** Confocal microscopy images of HEK 293 FT and DC 2.4 cells 24 hr post-transfection with αCD19-variable light chain GFP plasmid. **(D)** Confocal microscopy images of HEK 293 FT and DC 2.4 cells 24 hr post-transfection with αCD19-variable heavy chain GFP plasmid. **(E)** Mean percentages of cells expressing scFv fragments 24 hr post-transfection (n=4). **(F)** Left: Illustration of mutated variable light chain. Right: Confocal microscopy images of HEK 293 FT and DC 2.4 cells 24 hr post-transfection with αCD19- mutated (linear) variable light chain. **(G)** Confocal microscopy images of HEK293FT and DC2.4 cells 24 hr post-transfection with 1/3 fragments of αCD19-variable light chain GFP plasmid. **(H)** Mean percentages of GFP-positive cells 24 hr post-transfection with different fragments of scFv-GFP in DC2.4 and RAW264.7 (n=4). Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t test (\*\* denote p<0.01, \*\*\* denote p<0.001, \*\*\*\* denote p<0.0001).

© 2024, BioRender Inc. Figure 3A, C and D was created using BioRender, and is published under a CC BY-NC-ND license. Further reproductions must adhere to the terms of this license.



**Figure 3—figure supplement 1.** Immunoglobulin structure of scFv does not prevent degradation by myeloid cells. **(A)** Representative confocal images of DC 2.4 transfected with αCD19 scFv fused to GFP at the carboxyl end. **(B)** Upper: Illustration of immunoglobulin loop fragment GFP. Lower: Confocal microscopy images of HEK293FT and DC2.4 24 hr post-transfection with immunoglobulin loop fragment. Results are from one representative experiment out of at least three performed.

© 2024, BioRender Inc. Figure 3—figure supplement 1A was created using [BioRender](#), and is published under a [CC BY-NC-ND](#) license. Further reproductions must adhere to the terms of this license.




**Figure 4.** scFv fragments induce ER stress in myeloid cells. **(A)** Confocal microscopy imaging of RAW 264.7 24 hr post-transfection with linear mRNA vectors translating to GFP and  $\alpha$ CD19-scFv GFP. **(B)** qPCR data showing relative mRNA levels in RAW 264.7 transfected with GFP, Fc receptor-GFP, and  $\alpha$ CD19-scFv GFP (n=4). **(C)** Upper: Illustration of plasmid subunits. Lower: Confocal microscopy imaging of HEK293FT and RAW 264.7 24 hr post-transfection with T2A ribosomal skipping plasmid including ScFv. **(D)** Upper: Illustration of plasmid subunits. Lower: Confocal microscopy imaging of

Figure 4 continued on next page

*Figure 4 continued*

HEK293FT and RAW 264.7 24 hr post-transfection with plasmid not containing T2A. **(E)** Confocal microscopy images of RAW264.7 cells at 6 hr and 24 hr post-transfection with  $\alpha$ CD19-ScFv GFP plasmid. **(F)** Volcano plot showing differentially expressed proteins  $\alpha$ CD19 ScFv GFP and GFP in DC 2.4 cells. **(G)** Confocal microscopy images of DC 2.4 stained with an ER stain, 24 hr post-transfection with GFP, membranous TA99-ScFv GFP. **(H)** Confocal microscopy images of DC 2.4 stained for BiP 24 hr post-transfection. **(I)** Mean levels of phospho-JNK 6 hours following transfection (n=4). **(J)** Percentage of cells expressing GFP or TRP-TCR1 24 hr following transfection (n=3). Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t-test (\*\*\*\* denote  $p < 0.0001$ ).






**Figure 4—figure supplement 1.** scFv induces ER stress response in myeloid cells. **(A)** Illustration of experimental design. **(B)** Confocal microscopy images with staining for G3BP1 in DC2.4 cells 6 hr post-transfection with  $\alpha$ CD19 scFv. **(C)** Representative FACS analysis of HEK293FT and RAW 264.7 cells 24 hr post-transfection with TRP1-TCR. **(D)** Illustration of experimental design. **(E)** Representative analysis of CFSE dilution in CD8<sup>+</sup> and CD4<sup>+</sup> T cells following co-culture with ova conjugated scFv (n=4). Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t-test.

© 2024, BioRender Inc. Figure 4—figure supplement 1A, D was created using BioRender, and is published under a CC BY-NC-ND license. Further reproductions must adhere to the terms of this license.






**Figure 5.** FcγRI can provide a scaffold for incorporating IgM-induced signaling in myeloid cells and endows them with tumor cell-specific killing ability. (A) Illustration of chimeric Fcγ receptor design. (B–C) Representative FACS plots (B) and mean percentages (C) of RAW 264.7 cells expressing chimeric Fcγ receptors 24 hr after transfection (n=3). (D) Confocal microscopy images of RAW 264.7 cells 24 hr post-transfection with Fcγ receptors tagged with GFP and membrane-tagged tdTomato. (E) Mean percentages of BMDC 72 hr post lentivirus transduction with Fcγ receptors (n=4). (F) Confocal

Figure 5 continued on next page

*Figure 5 continued*

microscopy staining of GrB in RAW 264.7 cells co-cultured overnight with 4T1 cells expressing human HER2. **(G)** Mean counts of GrB in the synapse between transduced RAW 264.7 cells and the tumor cells (n=18). **(H)** IncuCyte analysis of human HER2<sup>+</sup> 4T1 cells growth following incubation with transduced RAW 264.7 cells (n=6). **(I)** Super-resolution microscopy of GFP-tagged chimeric FcγR and mCherry-tagged gamma chain. **(J)** IncuCyte analysis of human HER2<sup>+</sup> 4T1 cells growth following incubation with transduced RAW 264.7 cells (n=6). **(K)** Tumor size measurements (mm<sup>2</sup>) in mice treated with mRNA transfected BMDC with and without antibody. Arrows point to subcutaneous injection of treated BMDC (n=5). **(L)** Mean percentages of CD3<sup>+</sup> out of CD45<sup>+</sup> cells in B16F10 tumors from day 26 (n=4). Results are from one representative experiment out of at least three performed. Statistical significance was calculated using non-parametric t test (\*\* denote p<0.01, \*\*\*\* denote p<0.0001).

© 2024, BioRender Inc. Figure 5A was created using [BioRender](#), and is published under a [CC BY-NC-ND](#) license. Further reproductions must adhere to the terms of this license.



**Figure 5—figure supplement 1.** Fc $\gamma$ RI can be used as a scaffold to transmit IgM-induced signaling. **(A)** Representative confocal staining of Granzyme B in transduced RAW 264.7 cells incubated overnight with 4T1 cells expressing human HER2 antigen. **(B)** Super-resolution microscopy of RAW 264.7 cells transfected with chimeric Fc $\gamma$ RI molecules as such, or one hour after addition of free antibody. **(C)** Illustration of receptor design. **(D)** Mean percentages of RAW 264.7 cells expressing chimeric receptor (n=4). **(E)** Representative microscopy of RAW 264.7 cells co-transfected with GFP-fused chimeric

Figure 5—figure supplement 1 continued on next page

*Figure 5—figure supplement 1 continued*

receptor and mCherry-membrane protein. **(F)** Super-resolution microscopy of RAW 264.7 cells transfected with chimeric FcγRI molecules as such, or one hour after addition of free antibodies. **(G)** Confocal microscopy staining of GrB in RAW 264.7 cells co-cultured overnight with 4T1 cells expressing human HER2. **(H)** Illustration of experimental setting. **(I)** Representative photomicrographs of tumor-bearing mice 26 days after tumor injection. Results are from one representative experiment out of at least three independent experiments performed.

© 2024, BioRender Inc. Figure 5—figure supplement 1C, H was created using [BioRender](#), and is published under a [CC BY-NC-ND](#) license. Further reproductions must adhere to the terms of this license.